Retatrutide is an investigational GIP, GLP-1, and glucagon triple-receptor agonist being studied for metabolic regulation, body-weight reduction, glucose control, and obesity-related conditions. Phase 3 research has reported substantial effects on weight and metabolic endpoints, but retatrutide remains investigational and is not FDA-approved. For research purposes only.
Retatrutide is an investigational GIP, GLP-1, and glucagon triple-receptor agonist being studied for metabolic regulation, body-weight reduction, glucose control, and obesity-related conditions. Phase 3 research has reported substantial effects on weight and metabolic endpoints, but retatrutide remains investigational and is not FDA-approved. For research purposes only.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
